Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound to reveal hidden bleeding after EMG in blood thinner users

NCT ID NCT07166302

Knowledge-focused Sponsor: Masaryk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is checking whether a common nerve test called needle EMG causes muscle bleeding in people taking blood thinners (DOACs). About 30 minutes after the test, researchers will use ultrasound to look for any small bleeds in the muscles where the needle went in. The goal is to find out if the procedure is safe for this group. 70 adults on DOACs are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could show that needle EMG is safe for people on blood thinners, helping doctors avoid unnecessary precautions.
What could go wrong
This is a small, early observational study (70 people) that only looks for bleeding right after the procedure. It cannot prove long-term safety or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing needle EMG examination in EMG laboratory

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures * Willing and able to comply with all protocol procedures * subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing. * no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken. Exclusion Criteria: * Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject * other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Direct acting anticoagulant adverse reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma mononeuropathy neuromuscular disease peripheral nervous system disorder polyneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Direct acting anticoagulant adverse reaction EMG Mononeuropathies Needle injury Neuromuscular diseases (NMD) Peripheral neuropathies Polyneuropathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Brno

    RECRUITING

    Brno, Czech Republic, 62500, Czechia

  • University hospital Brno

    RECRUITING

    Brno, Czech Republic, 62500, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.